Sporadic endocrine tumours and their relationship to the hereditary endocrine neoplasia syndromes

European Journal of Clinical Investigation

Volumn 30, Issue 6, 2000, Pages 493-500

  Koper, Jan W ^a,b   Lamberts, S W J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOCRINE TUMOR; GENE ACTIVATION; GERM LINE; HUMAN; MOLECULAR CLONING; MULTIPLE ENDOCRINE NEOPLASIA; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

CARCINOMA, MEDULLARY; FAMILY HEALTH; GERM-LINE MUTATION; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; THYROID NEOPLASMS;

EID: 0034087242     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00666.x     Document Type: Review

References (76)

1. 1 Roijers JFM, de Wit MJ, van der Luijt RB, Ploos van Amstel HK, Lips CJM. MEN 1 case-finding: criteria for mutation analysis in MEN 1 suspected patients. Eur J Clin Invest 2000;30:487-92.
2. 2 Latif F, Tory K, Gnarra J, Yao M, Dun FM, Orcutt ML et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
3. 3 Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E et al. Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
4. 4 Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-6.
5. 5 Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-6.
6. 6 Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994;3:237-41.
7. 7 Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-7.
8. 8 Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997;6:1177-83.
9. 9 Ponder B. Genetic testing for cancer risk. Science 1997;278:1050-4.
10. 10 van der Harst E, de Krijger RR, Dinjens WN, Weeks LE, Bonjer HJ, Bruining HA et al. Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer 1998;77:337-40.
11. 11 Goretzki PE, Hoppner W, Dotzenrath C, Clark OH, Simon D, Cupisti K et al. Genetic and biochemical screening for endocrine disease. World J Surg 1998;22:1202-7.
12. 12 Krawczak M, Cooper DN. The human gene mutation database. Trends Genet 1997;13:121-2.
13. 13 Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994;3:1303-8.
14. 14 Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
15. 15 Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996;8:348-57.
16. 16 Oberstrass J, Reifenberger G, Reifenberger J, Wechsler W, Collins VP. Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system. J Pathol 1996;179:151-6.
17. 17 Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
18. 18 Gallou C, Joly D, Mejean A, Staroz F, Martin N, Tarlet G et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999;13:464-75.
19. 19 Yang K, Lindblad P, Egevad L, Hemminki K. Novel somatic mutations in the VHL gene in Swedish archived sporadic renal cell carcinomas. Cancer Lett 1999;141:1-8.
20. 20 Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Farmer RJ et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993;329:1531-8.
21. 21 Hofstra RM, Stelwagen T, Stulp RP, de Jong D, Hulsbeek M, Kamsteeg EJ et al. Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. J Clin Endocrinol Metab 1996;81:2881-4.
22. 22 Brauch H, Hoeppner W, Jahnig H, Wohl T, Engelhardt D, Spelsberg F et al. Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene. J Clin Endocrinol Metab 1997;82:4101-4.
23. 23 Bar M, Friedman E, Jakobovitz O, Leibowitz G, Lerer I, Abeliovich D et al. Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes. Clin Endocrinol (Oxf) 1997;47:707-12.
24. 24 Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Hofler H et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet 1995;95:551-6.
25. 25 Richards FM, Schofield PN, Fleming S, Maher ER. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 1996;5:639-44.
26. 26 Schoenfeld A, Davidowitz EJ, Burk RD. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 1998;95:8817-22.
27. 27 Iliopoulos O, Ohh M, Kaelin WG Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 1998;95:11661-6.
28. 28 Duan DR, Pause A, Burgess WH, Aso T, Chen DY, Garrett KP et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995;269:1402-6.
29. 29 Garrett KP, Tan S, Bradsher JN, Lane WS, Conaway JW, Conaway RC. Molecular cloning of an essential subunit of RNA polymerase II elongation factor SIII. Proc Natl Acad Sci USA 1994;91:5237-41.
30. 30 Aso T, Lane WS, Conaway JW, Conaway RC. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 1995;269:1439-43.
31. 31 Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93:10595-9.
32. 32 Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-39.
33. 33 Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA 1998;95:1630-4.
34. 34 Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY et al. Menin interacts with the API transcription factor JunD and represses JunD-activated transcription. Cell 1999;96:143-52.
35. 35 Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997;6:1169-75.
36. 36 Bassett JH, Forbes SA, Pannett AA, Lloyd SE, Christie PT, Wooding D et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998;62:232-44.
37. 37 Giraud S, Zhang CX, Serova-Sinilnikova O, Wautot V, -Salandre J, Buisson N et al. Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. Am J Hum Genet 1998;63:455-67.
38. 38 Weitzmann MN, Woodford KJ, Usdin K. DNA secondary structures and the evolution of hypervariable tandem arrays. J Biol Chem 1997;272:9517-23.
39. 39 Valdes N, Perez de Nanclares G, Alvarez V, Castano L, Diaz-Cadorniga F, Aller J et al. Multiple endocrine neoplasia type 1 (MEN1): clinical heterogeneity in a large family with a nonsense mutation in the MEN1 gene (Trp471Stop). Clin Endocrinol (Oxf) 1999;50:309-13.
40. 40 Thakker RV, Bassett JH, Forbes SA, Pannett AA, Lloyd SE, Christie PT et al. Multiple endocrine neoplasia - syndromes of the twentieth century. Characterization of mutations in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1998;83:2617-20.
41. 41 Carty SE, Helm AK, Amico JA, Clarke MR, Foley TP, Watson CG et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 1998;124:1106-13.
42. 42 Burgess JR, Greenaway TM, Shepherd JJ. Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. J Intern Med 1998;243:465-70.
43. 43 Heppner C, Kester MB, Agarwal SK, Debelenko LV, Emmert-Buck MR, Guru SC et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 1997;16:375-8.
44. 44 Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997;57:4682-6.
45. 45 Hessman O, Lindberg D, Skogseid B, Carling T, Hellman P, Rastad J et al. Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas. Cancer Res 1998;58:377-9.
46. 46 Debelenko LV, Brambilla E, Agarwal SK, Swalwell JI, Kester MB, Lubansky IA et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997;6:2285-90.
47. 47 Prezant TR, Levine J, Melmed S. Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors. J Clin Endocrinol Metab 1998;83:1388-91.
48. 48 Heppner C, Reincke M, Agarwal SK, Mora P, Allolio B, Burns AL et al. MEN1 gene analysis in sporadic adrenocortical neoplasms. J Clin Endocrinol Metab 1999;84:216-19.
49. 49 Schulte KM, Heinze M, Mengel M, Simon D, Scheuring S, Köhrer K et al. MEN I gene mutations in sporadic adrenal adenomas. Hum Genet. DOI 10.1007/s004399900193. 1999.
50. 50 Schulte KM, Mengel M, Heinze M, Simon D, Scheuring S, Köhrer K et al. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. J Clin Endocrinol Metab 2000;85:441-8.
51. 51 Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985;42:581-8.
52. 52 Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-63.
53. 53 Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. J Am Med Assoc 1996;276:1575-9.
54. 54 Eng C, Mulligan LM. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum Mutat 1997;9:97-109.
55. 55 Ponder BA, Smith D. The MEN II syndromes and the role of the ret proto-oncogene. Adv Cancer Res 1996;70:179-222.
56. 56 Shirahama S, Ogura K, Takami H, Ito K, Tohsen T, Miyauchi A et al. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma. J Hum Genet 1998;43:101-16.
57. 57 Durbec P, Marcos-Gutierrez CV, Kilkenny C, Grigoriou M, Wartiowaara K, Suvanto P et al. GDNF signalling through the Ret receptor tyrosine kinase. Nature 1996;381:789-93.
58. 58 Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M et al. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 1996;85:1113-24.
59. 59 Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA, Grigoriou M et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 1996;381:785-9.
60. 60 Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995;15:1613-19.
61. 61 Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ et al. RET activation by germline MEN2A and MEN2B mutations. Oncogene 1995;11:2419-27.
62. 62 Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995;267:381-3.
63. 63 Takahashi M, Asai N, Iwashita T, Murakami H, Ito S. Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations. Recent Results Cancer Res 1998;154:229-36.
64. 64 Zhou S, Carraway KL, 3rd, Eck MJ, Harrison SC, Feldman RA, Mohammadi M et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 1995;373:536-9.
65. 65 Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997;278:1043-50.
66. 66 Lips CJ. Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease. J Intern Med 1998;243:589-94.
67. 67 Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331:828-35.
68. 68 Lairmore TC, Frisella MM, Wells SA Jr. Genetic testing and early thyroidectomy for inherited medullary thyroid carcinoma. Ann Med 1996;28:401-6.
69. 69 Maruyama K, Tsukada T, Hosono T, Ohkura N, Kishi M, Honda M et al. Structure and distribution of rat menin mRNA. Mol Cell Endocrinol 1999;156:25-33.
70. 70 Ikeo Y, Sakurai A, Hashizume K. Characterization of the MEN1 gene product, menin, by site-specific polyclonal antibodies. Jpn J Cancer Res 1999;90:1088-95.
71. 71 Kim YS, Burns AL, Goldsmith PK, Heppner C, Park SY, Chandrasekharappa SC et al. Stable overexpression of MEN1 suppresses tumorigenicity of RAS. Oncogene 1999;18: 5936-42.
72. 72 Guru SC, Crabtree JS, Brown KD, Dunn KJ, Manickam P, Prasad NB et al. Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene. Mamm Genome 1999;10:592-6.
73. 73 Teh BT, Zedenius J, Kytola S, Skogseid B, Trotter J, Choplin H et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg 1998;228:99-105.
74. 74 Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A et al. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer 1995;76:479-89.
75. 75 Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F et al. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 1995;12:209-12.
76. 76 Mak YF, Ponder BA. RET oncogene. Curr Opin Genet Dev 1996;6:82-6.